(CercleFinance.com) – OSE Immunotherapeutics announces a progress report on Tedopi®, an immunotherapy for the activation of specific T lymphocytes against cancer cells, developed in advanced or metastatic non-small cell lung cancer (NSCLC) , in ovarian cancer and pancreatic cancer.
Tedopi® is the first therapeutic vaccine against cancer having shown clinically significant efficacy results associated with a better tolerance profile and quality of life versus comparator (reference treatment based on chemotherapy), indicates the laboratory.
The vaccine could potentially become a new reference treatment in non-small cell lung cancer after failure of immunotherapy.
Meetings are scheduled with regulatory agencies to validate the new protocol for the Phase 3 confirmatory clinical trial in NSCLC.